aTyr Pharma, Inc. Common Stock
ATYR Real Time Price USDRecent trades of ATYR by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in ATYR holdings by institutional investors
Quarterly net insider trading by ATYR's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
ATYR Estimated quarterly lobbying spending
ATYR Revenue by Segment or Geography
New ATYR patent grants
-
Patent Title: Aminoacyl trna synthetases for modulating inflammation Apr. 17, 2018
-
Patent Title: Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities Feb. 20, 2018
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases Feb. 20, 2018
-
Patent Title: Pegylated aspartyl-trna synthetase polypeptides Nov. 21, 2017
-
Patent Title: Aspartyl-trna synthetases Nov. 14, 2017
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases Oct. 24, 2017
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases Oct. 17, 2017
-
Patent Title: Pegylated tyrosyl-trna synthetase polypeptides Jul. 25, 2017
-
Patent Title: Aspartyl-trna synthetase-fc conjugates Jun. 27, 2017
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases Jun. 27, 2017
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases May. 02, 2017
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases Apr. 18, 2017
-
Patent Title: Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities Mar. 28, 2017
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases Mar. 14, 2017
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases Mar. 14, 2017
-
Patent Title: Histidyl-trna synthetase-fc conjugates Mar. 07, 2017
-
Patent Title: Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities Mar. 07, 2017
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-trna synthetases Feb. 28, 2017
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-trna synthetases Feb. 21, 2017
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl-trna synthetases Jan. 31, 2017
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase Jan. 10, 2017
-
Patent Title: Aminoacyl trna synthetases for modulating inflammation Jan. 10, 2017
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases Dec. 27, 2016
-
Patent Title: Thrombopoietic activity of tyrosyl-trna synthetase polypeptides Nov. 22, 2016
-
Patent Title: Polypeptide structural motifs associated with cell signaling activity Sep. 27, 2016
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases Aug. 30, 2016
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases Aug. 23, 2016
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetasis Aug. 23, 2016
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex Aug. 02, 2016
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl-trna synthetases Jul. 26, 2016
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases May. 24, 2016
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases May. 17, 2016
-
Patent Title: Amino acyl trna synthetases for modulating inflammation May. 03, 2016
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases Apr. 26, 2016
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases Apr. 26, 2016
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases Apr. 19, 2016
-
Patent Title: Histidyl-trna synthetases for treating autoimmune and inflammatory diseases Mar. 01, 2016
-
Patent Title: Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities Oct. 13, 2015
-
Patent Title: Aminoacyl trna synthetases for modulating inflammation Sep. 08, 2015
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases Jun. 30, 2015
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex Jun. 23, 2015
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-trna synthetases Jun. 23, 2015
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases May. 19, 2015
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases May. 19, 2015
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl-trna synthetases May. 19, 2015
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases May. 12, 2015
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases Apr. 07, 2015
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-trna synthetases Mar. 31, 2015
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-trna synthetases Mar. 24, 2015
-
Patent Title: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases Mar. 24, 2015
Federal grants, loans, and purchases
Estimated quarterly amount awarded to ATYR from public contracts
Recent insights relating to ATYR
Recent picks made for ATYR stock on CNBC
ETFs with the largest estimated holdings in ATYR
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ATYR stock a Buy, Sell, or Hold?
- What is the price target for $ATYR stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ATYR stock?
- Who owns the most shares of $ATYR stock?
- What funds own $ATYR stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ATYR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
- Address San Diego, CA
- Market Cap 76.0 million
- Employees 59
- Industrial Classification Biological Products, (No Disgnostic Substances)